Tirzepatide 60MG

Tirzepatide is a long‑acting, acylated 39‑amino‑acid peptide that functions as a dual incretin receptor agonist (GIPR and GLP‑1R). The GIP‑based backbone is lipidated with a C20 fatty‑diacid chain via a spacer on a lysine side‑chain to extend half‑life through albumin binding. Pharmacology spans appetite reduction, glucose‑dependent insulin secretion, suppression of glucagon, slowed gastric emptying, and weight loss. Regulatory approvals include use in adults with type 2 diabetes and chronic weight management; in 2024 the U.S. labeling was expanded to include treatment of moderate‑to‑severe obstructive sleep apnea (OSA) in adults with obesity.

 

Chemical Structure / Identifiers

Property	Detail
Class/Targets	Dual GIP and GLP‑1 receptor agonist
Backbone/Design	39‑aa peptide; Lys‑linked C20 fatty‑diacid for half‑life extension
Molecular Formula	C225H348N48O68 (PubChem)
Approx. Molecular Weight	≈ 4.9 kDa (varies by salt/hydration)
CAS Number	2023788‑19‑2
PubChem CID	156588324
US Brand Names (context)	Mounjaro (T2D); Zepbound (obesity/OSA)

 

Primary Research Focus / Clinical Effects

• Type 2 diabetes (SURPASS program): greater HbA1c reduction than semaglutide 1 mg and significant weight loss vs active comparator in SURPASS‑2.
• Obesity without diabetes (SURMOUNT‑1): ~15–21% mean weight reduction across 5–15 mg over 72 weeks vs placebo, with improved cardiometabolic markers.
• Obstructive sleep apnea (SURMOUNT‑OSA): in adults with obesity and moderate‑to‑severe OSA, 52 weeks of tirzepatide significantly reduced apnea–hypopnea index and body weight vs placebo in two phase 3 trials (with and without PAP therapy), supporting U.S. label expansion (2024/2025 updates).
• Ongoing outcomes & metabolic endpoints: continued evaluation of cardiovascular, hepatic and kidney outcomes across programs.

 

Safety / Limitations

• Common adverse effects: dose‑related gastrointestinal events (nausea, vomiting, diarrhea, constipation), most frequent during dose escalation.
• Boxed warning (class): risk of thyroid C‑cell tumors in rodents; contraindicated with personal/family history of medullary thyroid carcinoma (MTC) or MEN2.
• Other cautions: gallbladder disease; acute pancreatitis has been reported with incretin‑based therapies; hypoglycemia risk increases with insulin or secretagogues; potential diabetic retinopathy complications with rapid glycemic improvement; monitor renal status during severe GI events.
• Not indicated for type 1 diabetes or DKA; dosing, titration, and indications depend on current labeling.

 

Key Publications / References

PubChem Compound Summary: Tirzepatide (CID 156588324) – formula and structure. https://pubchem.ncbi.nlm.nih.gov/compound/156588324

Wikipedia overview (updated identifiers, indications). https://en.wikipedia.org/wiki/Tirzepatide

NEJM (2021) SURPASS‑2: Tirzepatide vs semaglutide in T2D. https://www.nejm.org/doi/full/10.1056/NEJMoa2107519  PubMed: https://pubmed.ncbi.nlm.nih.gov/34170647/

NEJM (2022) SURMOUNT‑1: Tirzepatide for obesity without diabetes. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038  PubMed: https://pubmed.ncbi.nlm.nih.gov/35658024/

NEJM (2024) SURMOUNT‑OSA: Tirzepatide for obstructive sleep apnea in adults with obesity. https://www.nejm.org/doi/full/10.1056/NEJMoa2404881  PubMed: https://pubmed.ncbi.nlm.nih.gov/38912654/

FDA Prescribing Information: Mounjaro (tirzepatide) for T2D (Initial U.S. Approval 2022). https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf

FDA Prescribing Information: Zepbound (tirzepatide) for chronic weight management and OSA (2024/2025 updates). https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217806Orig1s020lbl.pdf

 

Disclaimer: For research background only. Not medical advice. Indications and safety are governed by current prescribing information.